inocor

Inocor refers to a class of drugs known as phosphodiesterase inhibitors. These medications work by blocking the action of an enzyme called phosphodiesterase, which is responsible for breaking down cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). By inhibiting this enzyme, Inocor drugs increase the levels of cAMP and cGMP within cells, particularly in cardiac and vascular smooth muscle. This elevation in second messengers leads to vasodilation, meaning the blood vessels relax and widen, and also increases the contractility of the heart muscle. These combined effects result in a reduced workload for the heart and improved blood flow. Inocor drugs are primarily used in the short-term management of acute decompensated heart failure, a condition where the heart can no longer pump blood effectively. They can help to improve symptoms such as shortness of breath and fatigue by reducing pressure in the heart and increasing the heart's pumping strength. Examples of drugs in this class include milrinone and amrinone, although amrinone has largely been replaced by milrinone due to a better safety profile. Administration is typically through intravenous infusion. Potential side effects can include arrhythmias, hypotension, and gastrointestinal disturbances.